Biocon Limited has informed the Exchange regarding a press release dated December 23, 2025, titled "Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement".
Biocon Limited has informed the Exchange regarding a press release dated December 23, 2025, titled "Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement".